Navigation Links
PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
Date:2/3/2009

r the next year as we continue to work to develop additional innovative therapies for the muscular dystrophy community."

About DMD/BMD

Duchenne and Becker muscular dystrophy (DMD/BMD) are progressive muscle disorders that result in the loss of both muscle function and independence. DMD/BMD is perhaps the most prevalent form of the muscular dystrophies and is the most common lethal genetic disorder diagnosed during childhood today. Each year, approximately 20,000 children worldwide are born with DMD (one of every 3,500 male children). It is estimated that one in 10 DMD patients are likely to have a Becker presentation, a milder form of the disease that is associated with later manifestation of symptoms. Further information regarding DMD and BMD is available through the Muscular Dystrophy Association (www.mdausa.org), Parent Project Muscular Dystrophy (www.parentprojectmd.org) and the Association Francaise contre les Myopathies (www.afm-france.org).

About Ataluren (PTC124(TM))

Ataluren is an orally delivered, investigational new drug discovered by PTC Therapeutics. The drug is being developed as a new approach for the treatment of nonsense mutation genetic disorders. Nonsense mutations create a premature stop signal in the mRNA causing the ribosome to terminate translation before a full-length protein is generated. This causes the protein to be truncated and non-functioning. Ataluren is designed to allow the ribosome to continue translation of the mRNA, by overriding the premature stop signal leading to the formation of a functioning protein. Ataluren is a potential therapy for patients with nonsense mutation genetic disorders.

Ataluren has demonstrated proof of concept in Phase 2a clinical trials and is currently
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
2. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
3. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
4. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
5. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
6. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
7. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
8. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
9. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
10. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
11. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015 Among 1,000 U.S. ... yet only half of consumers surveyed are aware of ... ever used use them, according to findings from a ... community service partnership focused on improving the health and ... online survey polled 1,000 men and women, ages 21 ...
(Date:8/3/2015)... Aug. 4, 2015   The Intellectual Property ... world,s leading provider of intelligent information for businesses ... 2015 CMR Pharmaceutical R&D Factbook , the biopharmaceutical ... concerns around declines in R&D, the analysis identifies ... trillion milestone and forecasts sales to reach $1.3 ...
(Date:8/3/2015)... WARRINGTON, Pa. , Aug. 3, 2015 /PRNewswire/ ... a specialty biotechnology company focused on developing aerosolized ... a live teleconference and webcast at 8:30 a.m. Eastern ... time management will discuss the 2015 second quarter ... The company will issue a press release announcing ...
Breaking Medicine Technology:New Study Finds Consumers are Leaving Money at the Pharmacy 2New Study Finds Consumers are Leaving Money at the Pharmacy 3Pharma Sales to Grow Beyond $1 Trillion 2Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2
... Perceptive Informatics, the industry,s leading eClinical solutions provider ... PRXL ), today announced the results ... entitled "Optimizing Adaptive Trial Designs: Using Simulation ... by Perceptive Informatics with partner Cytel Inc., a ...
... Pharmaceuticals announced today positive results from its clinical ... Prednisporin(TM) (FOV1101) in patients with persistent allergic conjunctivitis.Prednisporin(TM) ... profile (no increase in intra-ocular pressure) than PredForte(TM), ... dose of prednisolone acetate, in patients treated for ...
Cached Medicine Technology:Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs 2Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs 3Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs 4Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs 5Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis 2Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis 3
(Date:8/4/2015)... ... August 04, 2015 , ... ... an automatic end to driving, says the August 2015 Harvard Health Letter. , ... to drive. It requires an individual assessment of skills," says Lissa Kapust, a ...
(Date:8/4/2015)... ... 2015 , ... Updated enrollment data on the top U.S. health plans, as ... at http://www.AISHealth.com . The data is free to all registered users to AISHealth.com. ... charts on the website’s “Data” section include:, , Top 25 ...
(Date:8/4/2015)... ... August 04, 2015 , ... The results of a three year clinical ... rare eye disease that progressively causes blindness, were published on June 23, 2015 in ... results of the trial, the implant, more commonly known as the “bionic eye,” is ...
(Date:8/4/2015)... Miramar Beach, FL (PRWEB) , ... August 04, 2015 , ... ... people are living with psoriatic disease and its uncomfortable symptoms such as dry, itching, ... suffer from psoriasis bounce from medication to medication before they find what’s right for ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... 20 finalists for America’s Favorite Veterinarian. The contest is put on by the ... committee from 500 nominees. Nominees were evaluated on community involvement, ethical behavior, passion ...
Breaking Medicine News(10 mins):Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 3Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 3
... Increases 32% to $14.2 Million ... Sets Quarterly Record, MINNEAPOLIS, Feb. 25 ATS Medical, ... products and services, today reported financial results for the,fourth quarter ... was $14.2 million, up 32.4% from $10.7 million reported in ...
... exhalations hint at wide range of conditions , , ... that uses laser light to sample a person,s breath ... number of diseases, a U.S. study says. , This ... one day help doctors screen patients for diseases such ...
... drugs is a worry, study says, , , MONDAY, Feb. 25 ... advanced dementia are given antibiotics in the last two weeks ... is whether or not that therapy has any benefits, such ... And, of concern are the risks associated with antibiotic use, ...
... Capital Growth Planning Inc., form "MaxLife-CGP",Partners LLC., a California based ... to $100M dollars in face value, of which ... ... CALIFORNIA, Feb. 25 /PRNewswire-FirstCall/ - MaxLife Fund Corp.,(OTC:MXFD). MaxLife ...
... A sophisticated robotic dog could be a good companion ... living pet, a new Saint Louis University study suggests. ... homes interacted with Sparky, a living, medium-sized gentle mutt, ... that looks like a three-dimensional cartoon. , The most ...
... Metalsmith Michael Aram,will lend his support to another noteworthy ... doors to his flagship store on March,13th for a special ... New Delhi based charity that was,established in 1994, at a ... Foundation has committed itself to raising awareness on and,preventing the ...
Cached Medicine News:Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 2Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 3Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 4Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 5Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 6Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 7Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 8Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 9Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 10Health News:Laser Screen Detects Diseases in Breath 2Health News:Antibiotic Use in Dementia Patients Questioned 2Health News:Antibiotic Use in Dementia Patients Questioned 3Health News:MaxLife Fund Corp. and Capital Growth Planning Inc., sign a joint venture agreement 2Health News:MaxLife Fund Corp. and Capital Growth Planning Inc., sign a joint venture agreement 3Health News:Faux Fido eases loneliness in nursing home residents as well as real dog, SLU study finds 2
Swiss Watchmaker Forceps, 4" extra-long precision ground points....
BB Watchmaker Forceps, Pakistan, 4.5" fine point....
Penfield Watchmaker Forceps. Tip width 0.9 mm....
Verte-Span is the latest advancement in vertebral body replacement technology. This device allows surgeons to reconstruct and stabilize certain types of anterior column defects in the spine....
Medicine Products: